TABLE 7.
Correlation between clinicopathological characteristics and PTX3 gene expression (GSE10846 dataset) in diffuse large B‐cell lymphoma (DLBCL)
| Variable | PTX3 | P value | |
|---|---|---|---|
| High | Low | ||
| Diagnosis | DLBCL | − | |
| Tissue | Lymph node | − | |
| Treatment | R‐CHOP‐like | − | |
| No. | 79/233 (34) | 154/233 (66) | − |
| Sex | |||
| Female | 69/99 (70) | 30/99 (30) | .318 |
| Male | 85/134 (63) | 49/134 (37) | |
| Age, y | |||
| ≤60 | 72/113 (64) | 41/113 (36) | .457 |
| >60 | 82/120 (68) | 38/120 (32) | |
| Ann Arbor stage | |||
| I‐II | 78/105 (74) | 27/105 (26) | .014 |
| III‐IV | 71/121 (59) | 50/121 (41) | |
| ECOG performance status | |||
| <2 | 116/158 (73) | 42/158 (27) | <.001 |
| ≥2 | 21/52 (40) | 31/52 (60) | |
| LDH ratio | |||
| <1 | 77 /99 (78) | 22/99 (22) | <.001 |
| >1 | 48/93 (52) | 45/93 (48) | |
| >1 extranodal site | |||
| 0‐1 | 117/173 (67) | 56/173 (32) | .062 |
| >1 | 15/30 (50) | 15/30 (50) | |
| NCCN‐IPI | |||
| Low+low‐intermediate risk | 73/101 (72) | 28/101 (28) | .010 |
| High+high‐intermediate risk | 33/63 (52) | 30/63 (48) | |
| Cell of origin | |||
| GCB | 71/107 (66) | 36/107 (34) | .938 |
| ABC+ unclassified | 83/126 (66) | 43/126 (34) | |
Data are shown n/N (%).
Abbreviations: −, no data; ABC, activated B‐cell‐like; GCB, germinal center B‐cell‐like; LDH, lactate dehydrogenase; NCCN‐IPI, National Comprehensive Cancer Network‐International Prognostic Index; R‐CHOP, rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone.